Wall Street Zen Upgrades NeuroOne Medical Technologies (NASDAQ:NMTC) to Hold

NeuroOne Medical Technologies (NASDAQ:NMTC) was upgraded by Wall Street Zen to a “hold” rating in a report released on Friday.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a research note on Saturday, September 27th. Maxim Group initiated coverage on shares of NeuroOne Medical Technologies in a research note on Tuesday, September 9th. They issued a “buy” rating and a $3.00 target price for the company. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, NeuroOne Medical Technologies currently has an average rating of “Hold” and an average target price of $2.23.

NeuroOne Medical Technologies Stock Performance

NASDAQ NMTC opened at $0.93 on Friday. The firm’s 50 day moving average price is $0.83 and its 200-day moving average price is $0.73. NeuroOne Medical Technologies has a 52-week low of $0.40 and a 52-week high of $1.39. The company has a market cap of $46.50 million, a PE ratio of -6.20 and a beta of 0.71.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. NeuroOne Medical Technologies had a negative net margin of 55.44% and a negative return on equity of 163.49%. The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.82 million. NeuroOne Medical Technologies has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NMTC. Warberg Asset Management LLC purchased a new position in NeuroOne Medical Technologies in the second quarter valued at $27,000. Jane Street Group LLC purchased a new position in NeuroOne Medical Technologies in the fourth quarter valued at $33,000. XTX Topco Ltd purchased a new position in NeuroOne Medical Technologies in the second quarter valued at $51,000. Cambridge Investment Research Advisors Inc. purchased a new position in NeuroOne Medical Technologies in the first quarter valued at $69,000. Finally, Goldman Sachs Group Inc. purchased a new position in NeuroOne Medical Technologies in the first quarter valued at $84,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.